CONTENTS:

Each month, PDSA highlights interesting findings and insightful expert commentary to help enhance your understanding of ITP and partner more effectively with your care team. This month, we share the following:


New ITP Treatment Shows Promise — Phase 2 Study Results

microscope

A small clinical trial testing an investigational medication called mezagitamab as a possible treatment for adults with primary immune thrombocytopenia (ITP) has been shown to be safe and effective.

This was a Phase 2 randomized trial, meaning participants were randomly assigned to receive either mezagitamab at different doses or a placebo (an inactive treatment) to see whether the drug could safely improve platelet levels. The study included adults whose ITP had lasted for at least three months. Mezagitamab is a monoclonal antibody that binds to CD38, a protein found on plasma cells. Plasma cells are the immune cells that produce antibodies, including the autoantibodies that mistakenly attack platelets in ITP.

Key Findings:

  • Patients treated with mezagitamab — especially at the higher 600 mg dose — had greater increases in platelet counts compared with those receiving placebo.
  • In one group, about 91% of participants on the 600 mg dose had a meaningful platelet response by week 16, compared with only about 23% of those on placebo.
  • Mezagitamab worked rapidly, with some people seeing platelet improvements within a couple of days.
  • The safety profile (side effects) was similar to placebo, with no major unexpected safety concerns in this trial.

What This Means for Patients:

These results suggest that mezagitamab may be a promising new therapy for people with ITP — helping to raise platelet counts and potentially reduce bleeding risk. However, this was a mid-stage study, and larger Phase 3 trials are underway to confirm how effective and safe mezagitamab is before it could become a widely recommended treatment option.

https://www.nejm.org/doi/full/10.1056/NEJMoa2513120

 


Watch Video: How Do You Manage Epistaxis (Nosebleeds)?


 

 

 


← Back to E-News